These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34778031)

  • 1. Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.
    Carinato H; Burgy M; Ferry R; Fischbach C; Kalish M; Guihard S; Brahimi Y; Flesch H; Bronner G; Schultz P; Frasie V; Thiéry A; Demarchi M; Petit T; Jung AC; Wagner P; Coliat P; Borel C
    Front Oncol; 2021; 11():714551. PubMed ID: 34778031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of weekly paclitaxel, carboplatin, and cetuximab in head and neck cancer patients with incurable disease.
    Narveson L; Kathol E; Rockey M; Henry D; Grauer D; Neupane P
    Med Oncol; 2016 Oct; 33(10):107. PubMed ID: 27568333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
    Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
    Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
    Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
    Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Rubió-Casadevall J; Cirauqui Cirauqui B; Martinez Trufero J; Plana Serrahima M; García Castaño A; Carral Maseda A; Iglesias Docampo L; Pérez Segura P; Ceballos Lenza I; Gutiérrez Calderón V; Fuster Salvà J; Pena Álvarez C; Hernandez I; Del Barco Morillo E; Chaves Conde M; Martínez Galán J; Durán Sánchez M; Quiroga V; Ortega E; Mesia R
    Front Oncol; 2023; 13():1226939. PubMed ID: 37601652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.
    Adkins D; Ley J; Atiq O; Powell S; Spanos WC; Gitau M; Rigden C; Palka K; Liu J; Oppelt P
    Oral Oncol; 2021 Apr; 115():105173. PubMed ID: 33548860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study.
    Pontes F; Garcia AR; Domingues I; João Sousa M; Felix R; Amorim C; Salgueiro F; Mariano M; Teixeira M
    Cancer Treat Res Commun; 2021; 27():100375. PubMed ID: 33882378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Bossi P; Miceli R; Locati LD; Ferrari D; Vecchio S; Moretti G; Denaro N; Caponigro F; Airoldi M; Moro C; Vaccher E; Sponghini A; Caldara A; Rinaldi G; Ferrau F; Nolè F; Lo Vullo S; Tettamanzi F; Hollander L; Licitra L
    Ann Oncol; 2017 Nov; 28(11):2820-2826. PubMed ID: 28950305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial).
    Tsakonas G; Specht L; Kristensen CA; Moreno MHC; Cange HH; Soderstrom K; Friesland S
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.
    Koyama T; Kiyota N; Boku S; Imamura Y; Shibata N; Satake H; Tanaka K; Hayashi H; Onoe T; Asada Y; Yamazaki T; Nose T; Ohata S; Nagatani Y; Kimbara S; Funakoshi Y; Teshima M; Shinomiya H; Minami H
    ESMO Open; 2024 Jun; 9(6):103476. PubMed ID: 38833968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Aguin S; Carral A; Iglesias L; Pena C; Molina A; Costa M; Covela M; Gomez JG; Arroyo RG; Huidobro G; Simo RV; Medina A
    Cancer Diagn Progn; 2023; 3(2):264-271. PubMed ID: 36875311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey.
    Burgy M; Barthélémy P; Lefevre F; Dupret-Bories A; Truntzer P; Korenbaum C; Flesch H; Bronner G; Borel C
    Oncology; 2017; 93(1):11-17. PubMed ID: 28423384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Cetuximab Plus Cisplatin Alone or in Combination With Paclitaxel in Patients With Head and Neck Squamous Cell Carcinoma: A Randomized Trial.
    Zheng Y; Dou H; Li Q; Sun Y; Wang Y; Zhang W
    Cancer Control; 2021; 28():1073274821997444. PubMed ID: 34029149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin in combination with weekly Paclitaxel as first-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma unfit to EXTREME schedule.
    Pêtre A; Dalban C; Karabajakian A; Neidhardt EM; Roux PE; Poupart M; Deneuve S; Zrounba P; Fayette J
    Oncotarget; 2018 Apr; 9(31):22038-22046. PubMed ID: 29774120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Takeshita N; Enokida T; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Tanaka N; Onaga R; Hoshi Y; Sakashita S; Ishii G; Tahara M
    Oral Oncol; 2023 Dec; 147():106615. PubMed ID: 37931493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab combined with paclitaxel or paclitaxel alone for patients with recurrent or metastatic head and neck squamous cell carcinoma progressing after EXTREME.
    Chevalier T; Daste A; Saada-Bouzid E; Loundou A; Peyraud F; Lambert T; Le Tourneau C; Peyrade F; Dupuis C; Alfonsi M; Fayette J; Reure J; Huguet F; Fakhry N; Toullec C; Salas S
    Cancer Med; 2021 Jun; 10(12):3952-3963. PubMed ID: 34080776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy.
    Marín-Jiménez JA; Oliva M; Peinado Martín P; Cabezas-Camarero S; Plana Serrahima M; Vázquez Masedo G; Lozano Borbalas A; Cabrera Martín MN; Esteve A; Iglesias Moreno MC; Vilajosana Altamis E; Arribas Hortigüela L; Taberna Sanz M; Pérez-Segura P; Mesía R
    Front Oncol; 2022; 12():953020. PubMed ID: 35936723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.
    Guo Y; Luo Y; Zhang Q; Huang X; Li Z; Shen L; Feng J; Sun Y; Yang K; Ge M; Zhu X; Wang L; Liu Y; He X; Bai C; Xue K; Zeng Y; Chang X; Chen W; Lin T
    Eur J Cancer; 2021 Oct; 156():35-45. PubMed ID: 34418665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of weekly paclitaxel plus cetuximab is comparable to the EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma.
    Motai R; Sawabe M; Kadowaki S; Sasaki E; Nishikawa D; Suzuki H; Beppu S; Terada H; Hanai N
    Int J Clin Oncol; 2021 Jul; 26(7):1188-1195. PubMed ID: 33821363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of neoadjuvant chemotherapy with paclitaxel, carboplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Tanaka R; Ueki Y; Ohshima S; Omata J; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Ohtaki K; Togashi T; Horii A
    Int J Clin Oncol; 2024 Aug; 29(8):1133-1141. PubMed ID: 38727853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.